White Paper
CertisAI Predictive Oncology Intelligence™ for Early Drug Development
AI‑Driven Efficacy Forecasts
Leverage tumor gene‑expression signatures to predict single‑agent and combination therapy responses before any bench work.
Instant Cancer‑Type Insights
Tap into 12 pre‑trained, indication‑specific models (from lung to skin cancer) or fine‑tune a custom model for your novel compound.
Comprehensive In Silico Library
Screen 2,200+ FDA‑approved drugs and over 1.9 billion potential combinations to pinpoint your highest‑value candidates.
Biomarker & Model Selection
Identify predictive gene signatures, optimal PDX/CCLE models, and companion‑diagnostic opportunities early in development.
Faster Leaner Development
Reduce costs, accelerate go/no‑go decisions, and minimize animal use with data‑driven guidance every step of the way.
Your Translational Partner
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is Certis Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with AI-driven bioinformatics. Our functional platform informs individual treatment and drug development decisions. Certis incorporates both 3D cell-based assays and in silico models to accelerate the development of new cancer therapies and reduce the number of animal models.